HALO Precision Diagnostics Appoints Thomas P. Slavin, M.D., as Chief Scientific Officer
Former Myriad CMO and Genetics Leader to Oversee Scientific Operations and Innovation for HALO’s Precision Diagnostic Offerings
MENLO PARK, Calif.–(BUSINESS WIRE)–HALO Precision Diagnostics (“HALO”), a leader in early disease detection using precision diagnostics, today announced the appointment of Thomas P. Slavin, M.D., as chief scientific officer.
Slavin is triple-board-certified in clinical genetics, molecular diagnostics, and pediatrics. He will lead scientific operations and innovation at HALO, supporting the continued evolution of the company’s robust imaging and precision diagnostic offerings across its growing network of owned and partner precision diagnostic centers.
“Dr. Slavin is a highly respected clinical leader and scientist in genetic testing,” said Michael Uhl, HALO chief executive officer. “We are fortunate to welcome him to HALO as we further our mission to save lives with early disease detection.”
HALO’s molecular diagnostics approach, in combination with its proprietary precision diagnostics platform, integrates advanced imaging to deliver comprehensive clinical insights for early disease detection and treatment. HALO currently has clinically validated care pathways for prostate cancer, breast cancer, and cardiovascular disease, as well as programs in development for neurodegenerative and other life-threatening diseases.
“I have dedicated my career to bringing genetic solutions to patients through education, research, and advocacy,” said Slavin. “HALO’s integrated approach to early disease detection is incredibly unique and I look forward to contributing to the company’s life-saving work.”
Most recently, Slavin served as chief medical officer at Myriad Genetics. He is an expert in hereditary cancer genetics and cancer screening and prevention, with extensive expertise in oncology product commercialization and evaluating molecular diagnostic technologies.
Slavin is a renowned speaker and researcher in the field of medical genetics, publishing more than 80 journal articles collectively evaluating genomic data from more than 500,000 patients.
Last month, HALO announced the appointment of John Craighead, Ph.D., as chief operating officer and chief financial officer.
About HALO Precision Diagnostics
HALO Precision Diagnostics is a leader in early disease detection using precision diagnostics. The company integrates advanced imaging with molecular diagnostics to deliver comprehensive clinical insights for early disease detection and to efficiently guide diagnosis and treatment for patients and physicians. With clinically validated care pathways dedicated to prostate cancer, breast cancer, cardiovascular and neurodegenerative diseases, HALO is increasing early disease detection and transforming lives. HALO currently serves one million patients, a number expected to triple by 2024. For more information visit www.HALOdx.com.
Contacts
HALO Media:
Meriel McCaffery
[email protected]
HALO Investors:
[email protected]
